Ascendiant Capital Markets reissued their buy rating on shares of Pro-Dex, Inc. (NASDAQ:PDEX) in a research report sent to investors on Friday, September 8th. The firm currently has a $9.00 price target on the medical instruments supplier’s stock, up from their previous price target of $8.00.
Pro-Dex (PDEX) traded up 4.20% during mid-day trading on Friday, hitting $7.45. The stock had a trading volume of 21,204 shares. Pro-Dex has a 1-year low of $3.80 and a 1-year high of $7.90. The company has a market cap of $29.99 million, a P/E ratio of 5.96 and a beta of -0.42. The company has a 50-day moving average price of $6.63 and a 200 day moving average price of $5.65.
ILLEGAL ACTIVITY NOTICE: “Ascendiant Capital Markets Reiterates Buy Rating for Pro-Dex, Inc. (NASDAQ:PDEX)” was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.truebluetribune.com/2017/09/16/pro-dexs-pdex-buy-rating-reaffirmed-at-ascendiant-capital-markets.html.
Pro-Dex Company Profile
Pro-Dex, Inc (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through four segments: Pro-Dex, OMS, Fineline and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce.
Receive News & Ratings for Pro-Dex Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pro-Dex Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.